• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[家族性高胆固醇血症的诊断与治疗]

[Diagnosis and Treatment of Familial Hypercholesterolemia].

作者信息

Schöb Manuela, Müller Pascal, Gerth Yannick, Korte Wolfgang, Rickli Hans, Brändle Michael, Bärlocher Andreas, Bilz Stefan

机构信息

1 Klinik für Endokrinologie, Diabetologie, Osteologie und Stoffwechselkrankheiten, Kantonsspital St. Gallen.

2 Pädiatrische Gastroenterologie & Ernährungsmedizin, Ostschweizer Kinderspital, St. Gallen.

出版信息

Praxis (Bern 1994). 2018 Nov;107(24):1345-1353. doi: 10.1024/1661-8157/a003134.

DOI:10.1024/1661-8157/a003134
PMID:30482120
Abstract

Diagnosis and Treatment of Familial Hypercholesterolemia Abstract. Familial hypercholesterolemia secondary to heterozygous mutations in the LDL receptor, Apolipoprotein B or PCSK9 gene is characterized by 2- to 3-fold elevated LDL cholesterol levels, premature atherosclerosis and extravascular cholesterol deposits (tendon xanthomata, corneal arcus). The same phenotype may occur if a person carries several LDL cholesterol rising polymorphisms (polygenic FH). Primary prevention with statins has been shown to dramatically reduce the cardiovascular burden in patients with the disease. However, it is estimated that less than 10 % of affected subjects in Switzerland have received the diagnosis, and undertreatment is frequent. Thus, clinical cardiovascular events are still the first manifestation of the disease in many cases. A correct diagnosis in index patients and cascade screening of families are mandatory to identify and treat patients before they suffer the sequelae of untreated severe hypercholesterolemia. In patients with clinical cardiovascular disease combination lipid lowering treatment with potent statins, ezetimibe and the newly available PCSK9 inhibitors will successfully lower LDL cholesterol to normal or even target levels.

摘要

家族性高胆固醇血症的诊断与治疗 摘要。由低密度脂蛋白受体、载脂蛋白B或前蛋白转化酶枯草溶菌素9(PCSK9)基因杂合突变引起的家族性高胆固醇血症的特征是低密度脂蛋白胆固醇水平升高2至3倍、早发性动脉粥样硬化和血管外胆固醇沉积(腱黄瘤、角膜弓)。如果一个人携带多个使低密度脂蛋白胆固醇升高的多态性(多基因家族性高胆固醇血症),也可能出现相同的表型。他汀类药物的一级预防已被证明可显著减轻该病患者的心血管负担。然而,据估计,瑞士不到10%的受影响患者得到了诊断,治疗不足的情况很常见。因此,在许多情况下,临床心血管事件仍是该病的首发表现。对索引病例进行正确诊断并对家族进行级联筛查,对于在患者遭受未经治疗的严重高胆固醇血症后遗症之前识别和治疗患者至关重要。对于患有临床心血管疾病的患者,联合使用强效他汀类药物、依泽替米贝和新上市的PCSK9抑制剂进行降脂治疗,将成功地将低密度脂蛋白胆固醇降至正常甚至目标水平。

相似文献

1
[Diagnosis and Treatment of Familial Hypercholesterolemia].[家族性高胆固醇血症的诊断与治疗]
Praxis (Bern 1994). 2018 Nov;107(24):1345-1353. doi: 10.1024/1661-8157/a003134.
2
Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.杂合子家族性高胆固醇血症患者的致病突变与早发性心血管疾病
Eur J Prev Cardiol. 2017 Jul;24(10):1051-1059. doi: 10.1177/2047487317702040. Epub 2017 Mar 29.
3
Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.降低家族性高胆固醇血症患者的心血管风险:风险预测和血脂管理。
Prog Cardiovasc Dis. 2019 Sep-Oct;62(5):414-422. doi: 10.1016/j.pcad.2019.10.003. Epub 2019 Oct 25.
4
Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.在他汀类药物或依折麦布治疗家族性高胆固醇血症患者时对 LDL 胆固醇基线浓度的推断。
Clin Chem. 2018 Feb;64(2):355-362. doi: 10.1373/clinchem.2017.279422. Epub 2017 Oct 16.
5
[Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].[作为罕见病的高脂蛋白血症和血脂异常。诊断与治疗]
Vnitr Lek. 2016 Fall;62(11):887-894.
6
Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland.冰岛大规模筛查单基因和临床定义的家族性高胆固醇血症。
Arterioscler Thromb Vasc Biol. 2021 Oct;41(10):2616-2628. doi: 10.1161/ATVBAHA.120.315904. Epub 2021 Aug 19.
7
Severe xanthomatosis in heterozygous familial hypercholesterolemia.杂合子家族性高胆固醇血症的严重黄色瘤病。
J Clin Lipidol. 2018 Jul-Aug;12(4):872-877. doi: 10.1016/j.jacl.2018.03.087. Epub 2018 Apr 3.
8
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).Gemcabene 在纯合子家族性高胆固醇血症中的作用(来自 COBALT-1)。
Am J Cardiol. 2019 Dec 15;124(12):1876-1880. doi: 10.1016/j.amjcard.2019.09.010. Epub 2019 Sep 26.
9
The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.丹麦家族性高胆固醇血症的分子遗传基础与诊断
Dan Med Bull. 2002 Nov;49(4):318-45.
10
How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?有多少家族性高胆固醇血症患者符合使用前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂的条件?
Atherosclerosis. 2017 Jul;262:107-112. doi: 10.1016/j.atherosclerosis.2017.05.013. Epub 2017 May 12.